ADMS

Adamas Pharmaceuticals

ADMS

Overview Fund Trends Analyst Outlook Journalist POV

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 0%

Negative

Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline

NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline

$4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

$4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline

Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details

Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details

Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline

Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery

Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

See News Rankings